Axa
ACHL

Axa’s Achilles Therapeutics ACHL Stock Holding History

Axa’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-282,028
Closed -$270K – 1185
2023
Q1 		$270K Sell
282,028
-2,405
-0.8% -$2.61K ﹤0.01% 1040
2022
Q4 		$256K Sell
284,433
-1,423
-0.5% -$2.4K ﹤0.01% 1069
2022
Q3 		$646K Buy
285,856
+2,201
+0.8% +$6.23K ﹤0.01% 926
2022
Q2 		$715K Buy
283,655
+829
+0.3% +$2.05K ﹤0.01% 923
2022
Q1 		$832K Buy
282,826
+3
+0% +$11 ﹤0.01% 976
2021
Q4 		$1.42M Buy
282,823
+3,369
+1% +$20.4K ﹤0.01% 904
2021
Q3 		$2.18M Buy
279,454
+10,319
+4% +$67.9K 0.01% 844
2021
Q2 		$2.63M Buy
+269,135
New +$3.65M 0.01% 841

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
EdenTree Asset Management London, United Kingdom $332M AUM 16.64% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa's ACHL Position: Q2 2023 in Review

Axa sold out of Achilles Therapeutics (ACHL) in Q2 2023, closing a stake of 282,028 shares — an estimated $270K sold.

Axa first reported a position in ACHL in Q2 2021 and held it in 8 quarters. The position peaked at $2.63M in Q2 2021. 18 funds tracked by Wall St. Rank hold ACHL as of Q2 2023.

  • Axa reported no remaining Achilles Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Axa sold 282,028 Achilles Therapeutics shares in Q2 2023, an estimated $270K.
  • Axa first reported a position in Achilles Therapeutics in Q2 2021 and held it in 8 quarters.
  • Axa's Achilles Therapeutics position peaked at $2.63M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.